The reality is that if the first in human trial is a failure then we are done, so we are a one trick pony in that respect. There is no point getting excited about a separate indication like ANCA vasculitis right now. I’ve told you time and time before that a deal will not be forthcoming yet you still believe it just think it hinges on the manufacturing. You lap up everything the CEO says without questioning it.
Clearly I’ve been posting here for a while so haven’t waited for phase 1 trials to be over, but I’m realistic and don’t get swept away into exuberance.
Ann: Presentation to highlight broader potential of Deoxymabs, page-65
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(7.14%) |
Mkt cap ! $15.43M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $3.199K | 400.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 10282775 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2895032 | 6 |
View Market Depth
| Last trade - 10.07am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.001 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.7¢ | 675000 | ||
| Last updated 13.31pm 17/05/2024 ? | |||||
| PAB (ASX) Chart |